Ra Capital Management Reveals New Stake in Enanta Pharmaceuticals Inc (ENTA)

Peter Kolchinsky‘s Ra Capital Management disclosed a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). According to a 13G filing, the new positions amounts to 1.54 million shares, which represent 8.00% of the company’s common stock. 

Peter Kolchinsky

Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a biotechnology company focused on the research and development of small molecule drugs in the infectious disease field. The company aims to discover and develop novel inhibitors designed for use against the HCV (hepatitis C virus). In addition to the HCV programs, Enanta has created Bicyclolides - a class of antibiotics for the treatment of multi-drug-resistant bacteria. In March, 2013, the drug developer raised $56.00 million in an initial public offering, pricing the stock at $14.00 per share.  The same year, the company disclosed net losses of slightly more than $4.00 million with respective losses of $0.67 per share, beating market expectations ($-1.78) by more than 60.00%. Analysts estimate steady earnings growth for the period of 2014, predicting losses per share of $0.30 for the first quarter, but earnings per share of $1.45 for the whole year. In 2015, Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is expected to produce profits per share in the range of $3.00 to a high $16.00 per share. Average consensus recommendation for the company’s stock is “Buy”.

Managed by Mitchell Blutt, Consonance Capital Management is another large shareholder at Enanta Pharmaceuticals, holding more than 850,000 shares of the company as at the end of 2013 – a position worth $23.20 million.

A graduate from Harvard with a Ph.D. in virology, Peter Kolchinsky manages an equity portfolio concentrated almost entirely in the Healthcare Sector. The largest position in the portfolio (15.30%) belongs to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), in which Kolchinsky’s fund invested $77.60 million, holding nearly 23.40 million shares.

Recently, RA Capital disclosed a new passive stake of 1.44 million shares in Repros Therapeutics Inc (NASDAQ:RPRX). Also, the fund boosted its position in pSivida Corp. (NASDAQ:PSDV) to 2.56 million shares – 6.20% of the company’s common stock.

Disclosure: none

Recommended Reading:

Ra Capital Management Initiates Stake in Furiex Pharmaceuticals Inc (FURX) After the Stock Jumped

Ra Capital Management Lowers Stake in Derma Sciences Inc (DSCI)

Trian Partners Discloses an Increased Position in Ingersoll-Rand PLC (IR)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!